Results 31 to 40 of about 23,238 (188)

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

OncoImmunology, 2017
The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse.
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi   +5 more
doaj   +1 more source

Altered Phenotypes of Colonic and Peripheral Blood Follicular Helper and Follicular Cytotoxic T Cells in Mice with DSS-Induced Colitis

Journal of Inflammation Research, 2023
Yan Long, Chang-Sheng Xia, Xingyue Zeng, Jinghong Feng, Yinting Ma, Chen Liu Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of ChinaCorrespondence: Yan Long; Chen Liu, Department of Clinical Laboratory,
Long Y, Xia CS, Zeng X, Feng J, Ma Y, Liu C   +5 more
doaj  

Drug Metabolism of Hepatocyte-like Organoids and Their Applicability in In Vitro Toxicity Testing

Molecules, 2023
Emerging advances in the field of in vitro toxicity testing attempt to meet the need for reliable human-based safety assessment in drug development. Intrahepatic cholangiocyte organoids (ICOs) are described as a donor-derived in vitro model for disease ...
Manon C. Bouwmeester, Yu Tao, Susana Proença, Frank G. van Steenbeek, Roos-Anne Samsom, Sandra M. Nijmeijer, Theo Sinnige, Luc J. W. van der Laan, Juliette Legler, Kerstin Schneeberger, Nynke I. Kramer, Bart Spee   +11 more
doaj   +1 more source

KLRG1 expression identifies short-lived Foxp3+ Treg effector cells with functional plasticity in islets of NOD mice

Autoimmunity, 2017
A progressive waning in Foxp3+ regulatory T (Treg) cell function provokes autoimmunity in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D), a cellular defect rescued by prophylactic IL-2 therapy.
Mara Kornete, Edward Mason, Roman Istomine, Ciriaco A. Piccirillo   +3 more
doaj   +1 more source

Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases

Diagnostics, 2022
Background: Pulmonary hypertension (PH) is a life-threatening complication of connective tissue diseases (CTD); in this study, we aimed at investigating the potential role of inducible co-stimulator (ICOS) and its ligand (ICOS-L) as biomarkers of PH in ...
Mattia Bellan, Francesco Murano, Federico Ceruti, Cristina Piccinino, Stelvio Tonello, Rosalba Minisini, Ailia Giubertoni, Daniele Sola, Roberta Pedrazzoli, Veronica Maglione, Giulia Francesca Manfredi, Antonio Acquaviva, Roberto Piffero, Giuseppe Patti, Mario Pirisi, Pier Paolo Sainaghi   +15 more
doaj   +1 more source

Transcriptome profile and clinical characterization of ICOS expression in gliomas

Frontiers in Oncology, 2022
Inducible co-stimulator (ICOS), an immune costimulatory molecule, has been found to play an essential role across various malignancies. This study investigated the transcriptome profile and clinical characterization of ICOS in gliomas.
Jin Wang, Fei Shi, Aijun Shan
doaj   +1 more source

Urbanonymic Terminology: Systems and Problems

Научный диалог, 2019
The article is focused on the problem of ordering and adaptation of modern Russian onomastic terminology to its foreign, especially Western European versions.
R. V. Razumov, S. O. Goryaev
doaj   +1 more source

Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies

Nature Communications, 2020
The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, binding its ligand (ICOS-L) on activated T cells. The structure of the ICOS/ICOS-L complex reveals a distinct receptor binding orientation.
Edurne Rujas, Hong Cui, Taylor Sicard, Anthony Semesi, Jean-Philippe Julien   +4 more
doaj   +1 more source

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system

OncoImmunology, 2019
Mice reconstituted with a human immune system and bearing human tumors represent a promising model for developing novel cancer immunotherapies. Here, we used mass cytometry and multi-parametric flow cytometry to characterize human leukocytes infiltrating
Aude Burlion, Rodrigo N. Ramos, Pukar KC, Kélhia Sendeyo, Aurélien Corneau, Christine Ménétrier-Caux, Eliane Piaggio, Daniel Olive, Christophe Caux, Gilles Marodon   +9 more
doaj   +1 more source

Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy

BMC Cancer, 2023
Background The immunological checkpoint known as Inducible T Cell Costimulatory Factor (ICOS, Cluster of Differentiation, CD278) is activated and expressed on T cells. Both somatic cells and antigen-presenting cells expressed its ligand, ICOSL (including
Xiashuang Zhao, Yongfeng Wang, Xianglai Jiang, Bangqian Mo, Chenyu Wang, Mingzheng Tang, Yao Rong, Guiqian Zhang, Ming Hu, Hui Cai   +9 more
doaj   +1 more source